arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Surrozen, Inc./DE

SRZN
$25.49 ▲ +3.80 (+17.52%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
26 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
79
Health
Good
Bullish
auto_awesome

Analytical Summary

Surrozen, Inc./DE shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth 408.6%
Op. Margin -209.1%
ROIC 3.0%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.00M
↑ +408.6%
Net Income Profit after all expenses
$-127.50M
↓ -372.8%
Operating Margin Operating profit as % of sales
-209.1%
↓ -1797.4%
FCF / Share Free cash flow per share
$-4.98
↓ -835.5%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Cash Quality
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters